These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33833333)

  • 1. Basmisanil, a highly selective GABA
    Hipp JF; Knoflach F; Comley R; Ballard TM; Honer M; Trube G; Gasser R; Prinssen E; Wallace TL; Rothfuss A; Knust H; Lennon-Chrimes S; Derks M; Bentley D; Squassante L; Nave S; Nöldeke J; Wandel C; Thomas AW; Hernandez MC
    Sci Rep; 2021 Apr; 11(1):7700. PubMed ID: 33833333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
    Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basmisanil, an α5-GABA
    Daher F; Villalobos NA; Hanley M; Atack JR; Popa MO; Fogaça MV
    Neurosci Lett; 2024 Jun; 833():137828. PubMed ID: 38772437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA
    Nickolls SA; Gurrell R; van Amerongen G; Kammonen J; Cao L; Brown AR; Stead C; Mead A; Watson C; Hsu C; Owen RM; Pike A; Fish RL; Chen L; Qiu R; Morris ED; Feng G; Whitlock M; Gorman D; van Gerven J; Reynolds DS; Dua P; Butt RP
    Br J Pharmacol; 2018 Feb; 175(4):708-725. PubMed ID: 29214652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA
    Goeldner C; Kishnani PS; Skotko BG; Casero JL; Hipp JF; Derks M; Hernandez MC; Khwaja O; Lennon-Chrimes S; Noeldeke J; Pellicer S; Squassante L; Visootsak J; Wandel C; Fontoura P; d'Ardhuy XL;
    J Neurodev Disord; 2022 Feb; 14(1):10. PubMed ID: 35123401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of a tonic inhibitory conductance in mouse hippocampal neurones by negative allosteric modulators of α5 subunit-containing γ-aminobutyric acid type A receptors: implications for treating cognitive deficits.
    Manzo MA; Wang DS; Li WW; Pinguelo A; Popa MO; Khodaei S; Atack JR; Ross RA; Orser BA
    Br J Anaesth; 2021 Mar; 126(3):674-683. PubMed ID: 33388140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABAA α5 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085.
    de Lucas AG; Ahring PK; Larsen JS; Rivera-Arconada I; Lopez-Garcia JA; Mirza NR; Munro G
    Biochem Pharmacol; 2015 Feb; 93(3):370-9. PubMed ID: 25542996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.
    Dawson GR; Maubach KA; Collinson N; Cobain M; Everitt BJ; MacLeod AM; Choudhury HI; McDonald LM; Pillai G; Rycroft W; Smith AJ; Sternfeld F; Tattersall FD; Wafford KA; Reynolds DS; Seabrook GR; Atack JR
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1335-45. PubMed ID: 16326923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABA
    Lewter LA; Fisher JL; Siemian JN; Methuku KR; Poe MM; Cook JM; Li JX
    ACS Chem Neurosci; 2017 Jun; 8(6):1305-1312. PubMed ID: 28150939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Benzodiazepine Ligand with Improved GABA
    Simeone X; Koniuszewski F; Müllegger M; Smetka A; Steudle F; Puthenkalam R; Ernst M; Scholze P
    Mol Pharmacol; 2021 Jan; 99(1):39-48. PubMed ID: 33268553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
    Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states.
    Drexler B; Zinser S; Huang S; Poe MM; Rudolph U; Cook JM; Antkowiak B
    Eur J Pharmacol; 2013 Mar; 703(1-3):18-24. PubMed ID: 23380687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the participation of peripheral α5 subunit-containing GABAA receptors in GABAA agonists-induced nociception in rats.
    Bravo-Hernández M; Feria-Morales LA; Torres-López JE; Cervantes-Durán C; Delgado-Lezama R; Granados-Soto V; Rocha-González HI
    Eur J Pharmacol; 2014 Jul; 734():91-7. PubMed ID: 24726872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects.
    Obradović ALj; Joksimović S; Poe MM; Ramerstorfer J; Varagic Z; Namjoshi O; Batinić B; Radulović T; Marković B; Roth BL; Sieghart W; Cook JM; Savić MM
    Brain Res; 2014 Mar; 1554():36-48. PubMed ID: 24472579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The orthosteric GABAA receptor ligand Thio-4-PIOL displays distinctly different functional properties at synaptic and extrasynaptic receptors.
    Hoestgaard-Jensen K; O'Connor RM; Dalby NO; Simonsen C; Finger BC; Golubeva A; Hammer H; Bergmann ML; Kristiansen U; Krogsgaard-Larsen P; Bräuner-Osborne H; Ebert B; Frølund B; Cryan JF; Jensen AA
    Br J Pharmacol; 2013 Oct; 170(4):919-32. PubMed ID: 23957253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABA
    Stamenić TT; Poe MM; Rehman S; Santrač A; Divović B; Scholze P; Ernst M; Cook JM; Savić MM
    Eur J Pharmacol; 2016 Nov; 791():433-443. PubMed ID: 27639297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Pharmacogenetic 'Restriction-of-Function' Approach Reveals Evidence for Anxiolytic-Like Actions Mediated by α5-Containing GABAA Receptors in Mice.
    Behlke LM; Foster RA; Liu J; Benke D; Benham RS; Nathanson AJ; Yee BK; Zeilhofer HU; Engin E; Rudolph U
    Neuropsychopharmacology; 2016 Sep; 41(10):2492-501. PubMed ID: 27067130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibition of extra-synaptic α5-GABA
    Etherington LA; Mihalik B; Pálvölgyi A; Ling I; Pallagi K; Kertész S; Varga P; Gunn BG; Brown AR; Livesey MR; Monteiro O; Belelli D; Barkóczy J; Spedding M; Gacsályi I; Antoni FA; Lambert JJ
    Neuropharmacology; 2017 Oct; 125():353-364. PubMed ID: 28807671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
    Atack JR
    Pharmacol Ther; 2010 Jan; 125(1):11-26. PubMed ID: 19770002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.